News | Artificial Intelligence | November 27, 2018

AI Promising in Predicting Chronic Conditions From CT Scans

Algorithms from Zebra Medical Vision successful in predicting osteoporotic fractures, cardiovascular disease

AI Promising in Predicting Chronic Conditions From CT Scans

November 27, 2018 – Zebra Medical Vision and Clalit Health Services announced the completion of two research projects that allow early identification of patients with bone and cardiovascular disease. Using existing computed tomography (CT) data, Zebra-Med’s artificial intelligence (AI) algorithms allow Clalit to identify patients at risk of osteoporotic fractures and cardiac events. Both research projects were independently validated by the Clalit Research Institute and will be presented for the first time during the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago.  

Clalit owns and operates 1,500 primary care clinics and 14 hospitals, including 30 percent of Israel’s hospital acute care beds, treating over 4 million patients.

Research #1 : “Automatic evaluation of CT scans for prediction of osteoporotic fractures”

In one of the largest osteoporosis experiments completed to date, a retrospective cohort of 48,227 individuals with abdominal CT studies, ages 50-90, was studied over five years. Patients were evaluated from the point of CT imaging to assess risk factors for the incidence of major and hip-specific osteoporotic fractures. The results showed that a combination of automatic Zebra-Med algorithms achieved equivalent risk-stratification compared with the contemporary Fracture Risk Assessment Tool (FRAX) scoring system. In addition, the research showed that the addition of Zebra-Med’s risk score to FRAX achieved results superior to those of FRAX alone.

If applied routinely to all CT studies of chest or abdomen, this would immediately stratify risks of osteoporotic fractures for all individuals over age 50. This would lead to secondary workup and possible prophylactic treatment. Currently, fewer than 20 percent of those at risk undergo routine screening but over 66 percent undergo routine CT studies. This illustrates the dramatic potential to increase awareness and prophylactic treatment in this growing population. Osteoporosis fractures cost $18 billion per year to the U.S. healthcare system and $3 billion to the U.K. National Health System (NHS).

Research #2:  “Incidental CT improves heart disease prediction”

A five-year retrospective cohort study of 14,135 patients with non-gated, unenhanced chest CT was used to examine the cardiovascular predictive power of Zebra-Med’s automatic coronary calcium scoring (CCS) algorithm. Prediction performance results were compared between the American Heart Association (AHA) 2013 predictive model (base model) and the same model with the Zebra-Med CCS inserted as an additional predictor (augmented model). The addition of Zebra-Med’s CCS improved sensitivity and specificity of the contemporary gold-standard AHA model, resulting in a net 4.5 percent categorical risk-reclassification improvement. The results indicate that by including a coronary calcium score derived by analyzing non-gated CT scans with Zebra-med’s algorithms, significant improvements in risk classification are achieved.  

According to the AHA, In 2016, cardiovascular disease (CVD) cost America $555 billion. By 2035, the cost will skyrocket to $1.1 trillion and by 2035, nearly half of the U.S. population will have some form of cardiovascular disease. Therefore, this research finding can help individuals and clinicians become aware of the risk stratification category for coronary vascular events in the next 10 years. This insight may lead to more tailored and preventative therapy.

“We are pleased with the results of these two groundbreaking research projects and are looking forward to get them into practice “ said Prof Ran Balicer , the head of Clalit’s Research Institute. “While there is an increasing number of AI applications in imaging, aiming to mimic and automate human radiologist reading, there is larger untapped potential in these imaging studies – one can use AI to extract predictive insights unavailable to date, that support high-impact population health interventions to tackle chronic diseases.”

For more information: www.zebra-med.com

Related Content

FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Graphic courtesy Pixabay

Graphic courtesy Pixabay

Feature | Artificial Intelligence | July 15, 2019 | By Greg Freiherr
Siemens has long focused on automation as a way to make diagnostic equipment faster and more efficient.
Videos | Artificial Intelligence | July 12, 2019
Khan Siddiqui, M.D., founder and CEO of HOPPR, discusses the economic advantages and costs presented by...
Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity.

Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity. UW-Madison was the first site in the U.S. to get this technology. Its use is now being integrated into UW CT protocols. Image courtesy of Timothy P. Szczykutowicz

Feature | Computed Tomography (CT) | July 12, 2019 | By Greg Freiherr
When providers develop their own imaging protocols, they are wasting time and money, according to...
Videos | Digital Pathology | July 11, 2019
Toby Cornish, M.D., Ph.D., associate professor and medical director of informatics at the University of Colorado Scho
Fluke Biomedical Introduces RaySafe 452 Survey Meter
Technology | Radiation Dose Management | July 11, 2019
Radiation measurement often requires different devices for varying applications, adding to the cost and complexity of...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Mednax National Cardiac Centers of Excellence Program Highlighted at SCCT 2019
News | CT Angiography (CTA) | July 11, 2019
Mednax Inc. and Mednax Radiology Solutions announced that Chief Medical Officer Ricardo C. Cury, M.D., FSCCT, will...
360 Photos | Ultrasound Imaging | July 11, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...